Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Hardman Johnston International Equity Cassandra A. Hardman | “AstraZeneca signed a deal with the U.S. administration to offer most-favored-nation (MFN) drug pricing to Medicaid patients and to participate in TrumpRx, a direct-to-consumer platform for purchasing prescription drugs. As part of the agreement, AstraZeneca received a three-year exemption from tariffs while committing to increased investment in its U.S. footprint. In our view, this outcome represents a best-case scenario for AstraZeneca and does not impact either near-term guidance or the company's 2030 financial targets. The company reiterated guidance, supported by broad-based strength across oncology, cardiology & renal, and rare disease despite macro headwinds throughout 2025. 2025 was a strong year of clinical success with more than 15 positive phase III trial readouts at major medical conferences. This data further underpins AstraZeneca's $80B revenue target for 2030. AstraZeneca is well positioned heading into 2026, with numerous additional Phase III readouts expected, providing continued momentum and further visibility toward achieving the 2030 $80B revenue goal. BSD Analysis: AstraZeneca has quietly assembled one of the strongest oncology and specialty pharma pipelines in the industry. Revenue diversification across geographies reduces policy risk. New indications continue extending product lifecycles. Emerging markets growth adds durability. Heavy R&D spend is translating into approvals, not just hope. Investors underestimate how balanced the portfolio has become. Margins improve as legacy investments mature. AstraZeneca is built for sustained growth, not one-hit wonders. This is scale pharma done right.” | BULL | Q4 2025 Dec 31, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
